N/A
N=20
Sex Differences in Vascular Responses to Exercise
Aging
Bottom Line
View on ClinicalTrials.gov: NCT04128215 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Nov 2024
Primary outcome: Primary: Change in FMD in Response to Chronic HIIT — 0.11; 0.57; 0.81; 0.10 % flow mediated dilation
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Control Period (Behavioral); Exercise Period (Behavioral)
- Age
- Adult, Older Adult · 60+ yrs
- Sex
- All
- Sponsor
- University of Florida
- Primary completion
- May 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in FMD in Response to Chronic HIIT |
0.11; 0.57; 0.81; 0.10 | — |
| PRIMARY Change in FMD in Response to Acute HIIT in the Untrained State |
-0.46; 0.19; -0.64; -1.28; -0.53; 0.12 | — |
| PRIMARY Change in FMD in Response to Acute HIIT in the Trained State |
0.77; -0.07; -0.66; -0.63; -0.45; 1.35 | — |
| PRIMARY Correlation Coefficient for the Relationship Between Acute and Chronic FMD Response to HIIT |
-0.32; -0.26; 0; -0.20; -0.17; 0.07 | — |
Summary
A key early event in cardiovascular disease development is endothelial dysfunction, characterized by impaired flow-mediated dilation. Regular aerobic exercise ameliorates endothelial dysfunction in healthy older men, but the data in healthy postmenopausal women are inconsistent with many studies showing no effect. The primary objective of this study was to examine sex differences in acute and chronic endothelial responses to exercise training in older men vs. older postmenopausal women.
Eligibility Criteria
Inclusion Criteria
- adults able to give consent
- men and women
- women must be postmenopausal (either natural or surgical)
- 60 to 79 years of age
Exclusion Criteria
- any relevant cardiovascular diseases (e.g., history of coronary artery bypass surgery or angioplasty, or heart failure, myocardial infarction, angina pectoris, peripheral arterial disease)
- myocardial ischemia during maximal graded exercise test
- major chronic clinical disease (e.g., diabetes, renal or hepatic disease or infection with hepatitis B, C, or HIV)
- seizures, or other relevant on-going or recurrent illness
- recent (within 3 months) or recurrent hospitalizations
- systolic blood pressure 35 kg/m^2
- >5% weight change in past 3 months or unwilling to remain weight stable during study participation
- use of tobacco products including smoking traditional or e-cigarettes
- use of hormone replacement therapy in women or men (e.g., estrogen, progesterone or testosterone)
- regular aerobic exercise training (≥30 min/session and ≥ 3 days/week)
Data sourced from ClinicalTrials.gov (NCT04128215). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.